Cassava Sciences, Inc. (SAVA)
| Market Cap | 1.85B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -20.83M |
| Shares Out | 40.38M |
| EPS (ttm) | -0.56 |
| PE Ratio | n/a |
| Forward PE | 101.01 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,964,340 |
| Open | 49.13 |
| Previous Close | 48.35 |
| Day's Range | 43.49 - 49.90 |
| 52-Week Range | 6.70 - 146.16 |
| Beta | 0.51 |
| Analysts | Buy |
| Price Target | 159.25 (+247.3%) |
| Earnings Date | Nov 8, 2021 |
About SAVA
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, T...
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for SAVA stock is "Buy." The 12-month stock price forecast is 159.25, which is an increase of 247.33% from the latest price.
News
CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cassava Sciences, Inc. on Behalf of Long-Term St...
NEW YORK--(BUSINESS WIRE)-- #Cassava--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cassava Sciences, Inc. (NASDAQ: SAVA) on...
While Cassava Sciences Is a Risky Play, It Has Substantial Payoff Potential
If you can stomach the volatility, you may want to enter an appropriately-sized position in SAVA stock. The post While Cassava Sciences Is a Risky Play, It Has Substantial Payoff Potential appeared firs...
Should Investors Worry About the Federal Investigation of Cassava?
The investigation really isn't the underlying concern.
Is the Options Market Predicting a Spike in Cassava Sciences (SAVA) Stock?
Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
Cassava Sciences Just Returned to the Buy Zone
There's no need to panic about SAVA stock, as Cassava Sciences just launched an important study focused on treating Alzheimer's disease. The post Cassava Sciences Just Returned to the Buy Zone appeared ...
Will Cassava Sciences Stock Continue To See Lower Levels?
The stock price of Cassava Sciences plunged 23% yesterday after a report that the U.S. SEC is investigating the company over allegations of data manipulation for its experimental Alzheimer's treatment -...
Cassava Sciences Kickstarts Second Late-Stage Alzheimer's Trial With Simufilam
Cassava Sciences Inc (NASDAQ: SAVA) has initiated a second Phase 3 study of simufilam in patients with Alzheimer's disease. The second Phase 3 study is designed to evaluate the safety and efficacy of o...
Cassava (SAVA) Down on Report of SEC Investigation Into AD Program
Cassava (SAVA) tanks on reports of an investigation by the SEC related to data reports on its AD candidate.
Cassava Sciences Initiates a Second Phase 3 Study of Simufilam for the Treatment of Patients with Alzheimer's Disease
Second Phase 3 Study is Designed to Evaluate Safety and Efficacy of Simufilam Over 78 Weeks in 1,000 Patients with Alzheimer's Disease Second Phase 3 Study is Designed to Evaluate Safety and Efficacy of...
3 Biotech Stocks That Have More Than Tripled so far This Year
But can they keep up the momentum?
See Why Cassava Sciences Shares Are Falling On Wednesday?
The Wall Street Journal reported that the SEC had launched a probe into claims that Cassava Sciences Inc (NASDAQ: SAVA) manipulated data key to its case for its experimental Alzheimer's drug simufilam. ...
Why Cassava Sciences Is Sliding Lower Today
Allegations of data manipulation that hammered the company -- and its stock price -- this summer won't be easily forgotten.
SAVA Stock Alert: The SEC Investigation That Has Cassava Sciences Cratering Today
Cassava Sciences (SAVA) stock is on the move Wednesday as investors react to reports of an SEC investigation over possible data manipulation. The post SAVA Stock Alert: The SEC Investigation That Has Ca...
7 Short-Squeeze Stocks Loaded With High-Risk, High-Reward Upside
Here are seven of the top short-squeeze stocks investors may want to keep their eye on, as retail investors lay and wait for the next squeeze. The post 7 Short-Squeeze Stocks Loaded With High-Risk, High...
Cassava Sciences Reports Third Quarter 2021 Financial Results
AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced financial results for the t...
Cassava Sciences Needs Time and Data to Prove Itself Before You Buy
Even as SAVA stock whipsaws in both directions, Cassava's commitment to treating Alzheimer's disease remains as firm and steady as ever. The post Cassava Sciences Needs Time and Data to Prove Itself Bef...
Cassava Is a Sell After Accusations of Data Manipulation
After Cassava was accused of multiple improprieties for its star Simufilam drug, investors should sell the vast majority of their SAVA stock. The post Cassava Is a Sell After Accusations of Data Manipul...
4 Top Biotech Stocks To Watch This Week
Check out these biotech stocks that could prove to be valuable additions to your portfolio.
Short Squeeze Stocks: PROG, SAVA and 3 Others Experts Think Are Ready to Pop
Fintel's list of short squeeze stocks to watch for this week is in. Here are the names that investors should be watching.
5 Short Squeeze Candidates To Watch: Progenity Tops List Again, Cassava Sciences Joins Following Short Report
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE:GME) or AMC Entertainment Holdings Inc (NYSE:AMC). A short squeeze can occur when...
Why Did Cassava Sciences Stock Jump 49% Today?
Journal of Neuroscience has informed Cassava Sciences Inc (NASDAQ: SAVA) that there is no evidence of data manipulation in an article published in July 2012 describing a new approach to treating Alzheim...
Why Cassava Sciences Shares Are Rising
Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading higher after a review by the Journal of Neuroscience showed there is no evidence of data manipulation in a 2012 company technical paper. "I've ne...
SAVA Stock Alert: Why Cassava Sciences Is Rocketing 50% Higher Today
Cassava Sciences just got good news. SAVA stock is soaring as the company celebrates the end of its manipulated data accusations.
Review by Journal of Neuroscience Shows No Evidence of Data Manipulation in Technical Paper Foundational to Cassava S...
It states, “No evidence of data manipulation was found for Western blot data.” It states, “No evidence of data manipulation was found for Western blot data.”
Is it too risky to buy Cassava Sciences as Quintessential says the stock is worthless?
On Wednesday, Cassava Sciences Inc. (NASDAQ:SAVA) shares plunged more than 7% after Quintessential Capital management released a report saying the stock is worthless. The firm called for shorts to swoop...